Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Metcalf who wrote (5135)	8/13/1998 12:36:00 PM
From: biodoc	Read Replies (1) of 6136

I have to jump in with a correction. HIV is NOT almost always transmitted to the child. Transmission rates depend on a number of things, but without maternal anti-retroviral therapy, the transmission rate in the U.S. ran around 25%. Since the institution of a regimen of AZT to the mother during pregnancy, IV during labor and to the baby for 6 weeks after delivery, the rate in a large controlled trial was about 8 %. In actual practice, in a number of studies the actual transmission rate in the US has been dramatically reduced. There is no evidence of any adverse effect of AZT when used in this way (it was not given in first trimester in these studies) There is evidence that with more complex treatment regimens for women, the transmission rate has become even lower. So---while it is correct to warn women about the unknown risk of some of the newer drugs, and women need to understand the actual risk of transmission, it is incorrect to start of with the assumption that HIV in almost always transmitted to the child. This has never been true at any time in the epidemic.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next